HONG KONG – Sinopharm Group, one of the largest biotech companies in China, is likely to undergo major structural reforms as the government kicks off a series of reforms on its state-owned enterprises (SOEs). Read More
SHANGHAI – Pharmamar SA, of Madrid, has licensed the commercial rights to Aplidin (plitidepsin), an antitumour agent for multiple myeloma used in conjunction with dexamethasone, to Chugai Pharmaceutical Marketing Ltd., the European arm of Japanese parent company Chugai Pharmaceutical. Read More
TOKYO – Rani Therapeutics LLC is working on a delivery system for insulin that could provide relief for millions of people who must undergo regular painful injections to deal with conditions such as diabetes, rheumatoid arthritis, osteoporosis and multiple sclerosis. Read More
HONG KONG — Defects in fatty acid-binding proteins (FABPs) may help to explain the pathology in some cases of schizophrenia and autism spectrum disorders (ASDs), possibly leading to the development of tailor-made therapies for those mental disorders, Japanese neuroscientists reported. Read More
SHANGHAI – HD Biosciences Co. Ltd. has signed an agreement to co-develop drugs with two research centers at Marshall University. The deal was struck after three years of informal collaboration between both sides, and with an eye to entering the clinic in the next two years. The focus of the alliance is to provide innovative medicines for unmet medical needs, particularly cancer and kidney fibrosis, in both China and the U.S. Read More
Sinovac Biotech Ltd., of Beijing, said it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the expanded program of immunization (EPI) for Beijing. The vaccines will be used for the period from 2014 to 2016, and the company expects to begin delivery in the coming months upon demand. Read More
